Rowland Charles A Jr
- SEC CIK
- 0001383292
In the past year, 1 open-market sale filing worth $2.13M and no purchases.
Current role at each company
- GBIO Generation Bio Co.Directoras of Feb 9, 2026
- VKTX Viking Therapeutics, Inc.Directoras of Jan 5, 2026
- ORTX Orchard Therapeutics plcDirectoras of Jan 24, 2024
- Nabriva Therapeutics plcDirectoras of Aug 3, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $2.13M
- 1 filing
- Net
- −$2.13M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Rowland Charles A Jr as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
VKTX Viking Therapeutics, Inc.
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 28, 2025 (view filing) | Oct 27 | 1 day | Rowland Charles A JrDirector | SSaleCommon Stock, par value $0.00001 per share | −60.0K | $35.57 | −$2.13M | −66.7%30.0K after | |
| May 18, 2023 (view filing) | May 16 | 2 days | Rowland Charles A JrDirector | SSaleCommon Stock, par value $0.00001 per share | −40.0K | $25.00 | −$1.00M | −57.1%30.0K after |
GBIO Generation Bio Co.
Director4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 5, 2023 (view filing) | Dec 1-4 | 4 days | Rowland Charles A JrDirector | PPurchase | +343.0K | $1.39 | +$477.8K | +178.8%534.8K after | 2 lots |
| Sep 20, 2022 (view filing) | Sep 19 | 1 day | Rowland Charles A JrDirector | PPurchase | +15.8K | $5.26 | +$82.8K | +8.9%191.8K after | |
| Sep 19, 2022 (view filing) | Sep 15-16 | 4 days | Rowland Charles A JrDirector | PPurchase | +50.6K | $5.46 | +$276.2K | +40.4%176.0K after | 2 lots |
| Sep 15, 2022 (view filing) | Sep 13-14 | 2 days | Rowland Charles A JrDirector | PPurchase | +24.4K | $5.22 | +$127.4K | +24.1%125.4K after | 2 lots |
Nabriva Therapeutics plc
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 3, 2022 (view filing)9:48 PM ET | Aug 1 | 2 days | Rowland Charles A JrDirector | SSale | −8.50K | $0.175 | −$1.49K | −35.7%15.3K after | |
| Aug 4, 2021 (view filing) | Aug 2 | 2 days | Rowland Charles A JrDirector | SSale | −777 | $1.20 | −$932.4 | −3.2%23.8K after |